The phase 3 SURPASS-4 trial published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than insulin glargine (a long-acting insulin) for type 2 diabetes (T2D).

Data from four tirzepatide pivotal trials in people with type 2 diabetes showed ≥15% weight loss in 25% of those on tirzepatide, ... (Mounjaro) and that sponsored the SURPASS trials.

"Results from SURPASS-SWITCH suggest that escalating dulaglutide is not as effective in reducing HbA1c and may further delay diabetes control than switching to tirzepatide," they wrote.

The phase 3 SURPASS trials published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than other drugs for type 2 diabetes (T2D) [1]. Now new research ...

Tirzepatide, a once-weekly dual ... analysis of data from the SURPASS-3 trial by Viljoen et al. revealed that the median time to first achieve the HbA1c of 7.0% was 8.1 weeks for each dose of ...

A recent post-hoc analysis of Lilly’s SURPASS-3 trial unravels the impact of tirzepatide treatment on muscle volume and fat infiltration in individuals with Type 2 Diabetes A recent post-hoc ...

Eli Lilly’s tirzepatide, approved for type 2 diabetes as Mounjaro, led to weight loss of 21% at the highest dose over a 72-week clinical trial on obesity, according to results published last ...

Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), ... Three different doses of tirzepatide were tested in SURPASS: 5mg, 10mg and 15mg.

Tirzepatide, a drug approved for the treatment of type 2 diabetes, could be on its way to becoming a new drug to treat obesity as well, now that the U.S. Food and Drug Administration (FDA) has ...

That trial, called SURPASS-CVOT, will finish in mid-2025 and could “really give us the details we need to see how effective tirzepatide is in reducing heart disease,” he says.

In the SURPASS clinical trial program (SURPASS 1-5; ClinicalTrials.gov; Identifiers: NCT03954834, NCT03987919, NCT03882970, NCT03730662, NCT04039503), the effect of tirzepatide for reducing ...

The current exploratory analysis of data from Lilly’s SURPASS-3 MRI study, described changes in the fat z-scores in people with T2D following treatment with once-weekly tirzepatide (5, 10 or 15 ...